Cabergoline

CHEMBL1201087 Phase 4 已批准 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
451.6 g/mol
LogP
3.4
Phase
4

A dopamine receptor agonist derived from ergot used to treat conditions of elevated prolactin including prolactinomas, and also for Parkinson's disease. It suppresses prolactin secretion from the pituitary gland, reducing symptoms such as irregular periods and unwanted milk production. Long-term use at high doses has been associated with cardiac valve abnormalities.

分子量

451.6000 g/mol

LogP

3.40

TPSA

71.70 Ų

Lipinski 五规则

符合

治疗领域

作用机制

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21

InChI

InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1

Molecular Formula

C26H37N5O2

HBD / HBA

2 / 4

可旋转键数

8

重原子数

33

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

A dopamine receptor agonist derived from ergot used to treat conditions of elevated prolactin including prolactinomas, and also for Parkinson's disease. It suppresses prolactin secretion from the pituitary gland, reducing symptoms such as irregular periods and unwanted milk production. Long-term use at high doses has been associated with cardiac valve abnormalities.

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

Yes, Cabergoline is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201087. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 54746. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.